Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 3:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ectasia of Cornea Clear all
Not listed Phase 3 Interventional Accepts healthy volunteers

Accelerated Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Pulse or Continuous UV-A Light

NCT05027295
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
riboflavin ophthalmic solution
Drug
Lead sponsor
Cornea and Laser Eye Institute
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 27, 2026, 3:32 PM EDT
No Longer Available No phase listed Expanded access Accepts healthy volunteers

Progressive Keratoconus or Ectasia Treatment Plan

NCT01384773
View directory record Official record
Conditions
Keratoconus, Ectasia
Interventions
Riboflavin Solution, UV-X Illumination System
Other · Device
Lead sponsor
Stephen Trokel
Other
Eligibility
16 Years and older
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 27, 2026, 3:32 PM EDT
Terminated Phase 3 Interventional

Safety & Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery

NCT01459679
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
KXL System (15 mW/cm2), KXL System (30 mW/cm2), KXL System (45 mW/cm2), riboflavin ophthalmic solution
Device · Drug
Lead sponsor
American-European Congress of Ophthalmic Surgery
Network
Eligibility
12 Years and older
Enrollment
1,721 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
82
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 71 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 27, 2026, 3:32 PM EDT
Terminated No phase listed Observational

Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas

NCT01189864
View directory record Official record
Conditions
Keratoconus, Ectasia, Degeneration
Interventions
Ciprofloxicin or Vigamox or other., Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc), Steroid (FML, Pred Forte, Flarex, etc.)
Drug
Lead sponsor
Cxlusa
Industry
Eligibility
12 Years and older
Enrollment
3,493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
16
States / cities
Scottsdale, Arizona • Laguna Hills, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 27, 2026, 3:32 PM EDT
Not listed Phase 3 Interventional

Corneal Collagen Crosslinking and Intacs for Keratoconus and Ectasia

NCT01112072
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
Riboflavin
Drug
Lead sponsor
Cornea and Laser Eye Institute
Other
Eligibility
21 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 27, 2026, 3:32 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Wavefront Guided Scleral Lenses for Keratoconus and Irregular Astigmatism

NCT04698590
View directory record Official record
Conditions
Keratoconus, Irregular Astigmatism, Corneal Ectasia, Aberration, Corneal Wavefront, Wavefront Aberration, Corneal, Pellucid Marginal Corneal Degeneration, Keratoglobus
Interventions
Wavefront Guided Scleral Lenses, Traditional Scleral Lenses
Device
Lead sponsor
Cornea and Laser Eye Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Sep 27, 2026, 3:32 PM EDT
Not listed Phase 1 Interventional

Study of the Safety and Effectiveness of Collagen Cross-Linking at an Irradiance of 9 mW/cm2 and 18 mW/cm2

NCT02009709
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
Riboflavin 0.1% ophthalmic solution, CCL-VARIO UV lamp, CCL-VARIO at 18 mW/cm2
Drug · Device
Lead sponsor
Robert Mack, M.D.
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Hoffman Estates, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 27, 2026, 3:32 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Transepithelial (Epi-on) Corneal Collagen Crosslinking to Treat Keratoconus and Corneal Ectasia

NCT04905108
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
Riboflavin
Drug
Lead sponsor
Cornea and Laser Eye Institute
Other
Eligibility
12 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 27, 2026, 3:32 PM EDT
Not listed Phase 1Phase 2 Interventional

Safety and Effectiveness of the PXL-Platinum 330 System

NCT04401865
View directory record Official record
Conditions
Corneal Ectasia, Keratoconus, Pellucid Marginal Corneal Degeneration
Interventions
PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Combination Product
Lead sponsor
Colorado Eye Consultants/Cornea Consultants of Colorado
Industry
Eligibility
8 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Littleton, Colorado • Highland Park, Illinois • Brecksville, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Sep 27, 2026, 3:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety & Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution

NCT04667572
View directory record Official record
Conditions
Keratoconus, Pellucid Marginal Corneal Degeneration, Corneal Degeneration, Corneal Ectasia
Interventions
PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Combination Product
Lead sponsor
Cornea Associates of Texas
Other
Eligibility
8 Years and older
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 27, 2026, 3:32 PM EDT
Terminated No phase listed Observational

Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas

NCT01024322
View directory record Official record
Conditions
Keratoconus, Ectasia, Degeneration
Interventions
Ciprofloxicine or Vigamox or other., Nonsteroidal (Acular, Voltaren Xibrom, etc), Steroid (FML, Pred Forte, Flarex, etc.)
Drug
Lead sponsor
Cxlusa
Industry
Eligibility
8 Years and older
Enrollment
1,189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
3
States / cities
Miami, Florida • Rockville, Maryland • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Sep 27, 2026, 3:32 PM EDT
Completed Phase 2Phase 3 Interventional

Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia

NCT00567671
View directory record Official record
Conditions
Progressive Keratoconus, Corneal Ectasia
Interventions
Corneal collagen, Sham comparator
Procedure
Lead sponsor
Emory University
Other
Eligibility
14 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2010 · Synced Sep 27, 2026, 3:32 PM EDT
Recruiting Phase 2 Interventional

Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia

NCT04094090
View directory record Official record
Conditions
Keratoconus, Pellucid Marginal Corneal Degeneration, Corneal Ectasia
Interventions
PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Combination Product
Lead sponsor
Goodman Eye Center
Other
Eligibility
10 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 27, 2026, 3:32 PM EDT
Completed Phase 3 Interventional Results available

Corneal Collagen Cross-Linking for Ectasia (CXL)

NCT00674661
View directory record Official record
Conditions
Ectasia
Interventions
riboflavin ophthalmic solution, UVA Irradiation
Drug · Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
14 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
10
States / cities
La Jolla, California • San Diego, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Sep 27, 2026, 3:32 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Corneal Crosslinking Using the PXL-Platinum 330 for Eyes With Corneal Ectatic Conditions

NCT04240457
View directory record Official record
Conditions
Keratoconus, Cornea Ectasia
Interventions
Epithelial-on Corneal Crosslinking with the PXL 330 Platinum system.
Combination Product
Lead sponsor
Arbor Center for Eye Care
Other
Eligibility
12 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Orland Park, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Sep 27, 2026, 3:32 PM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of the PXL Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Position

NCT04213885
View directory record Official record
Conditions
Keratoconus, Unstable, Ectasia Corneal, Bacterial Keratitis
Interventions
PXL 330 Platinum device/Riboflavin
Combination Product
Lead sponsor
Eye Specialists of Indiana
Other
Eligibility
12 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Sep 27, 2026, 3:32 PM EDT
Not listed Phase 3 Interventional

Corneal Cross-Linking Comparing Variables

NCT02095730
View directory record Official record
Conditions
Unstable Corneas
Interventions
Epithelium-On Riboflavin, Epithelium-Off Riboflavin, UV Light - Continuous Beam, UV Pulsed Beam
Drug · Device
Lead sponsor
Crowd Health Research, LTD
Other
Eligibility
12 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
16
States / cities
Santa Rosa, California • Denver, Colorado • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2014 · Synced Sep 27, 2026, 3:32 PM EDT
Completed Phase 1 Interventional

Safety and Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution

NCT04177082
View directory record Official record
Conditions
Keratoconus, Pellucid Marginal Corneal Degeneration, Corneal Degeneration, Corneal Ectasia
Interventions
PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Combination Product
Lead sponsor
Cornea Associates of Texas
Other
Eligibility
8 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Sep 27, 2026, 3:32 PM EDT
Recruiting Phase 2Phase 3 Interventional

Corneal Crosslinking for Treatment of Progressive Keratoconus or Corneal Ectasia

NCT07841470
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
Riboflavin 0.1% ophthalmic solution and pulsed light, Riboflavin 0.1% ophthalmic solution and non-pulsed light
Combination Product
Lead sponsor
Price Vision Group
Industry
Eligibility
10 Years to 90 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 27, 2026, 3:32 PM EDT
Not listed Phase 3 Interventional

Transepithelial Corneal Collagen Crosslinking for Keratoconus and Corneal Ectasia

NCT01464268
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
Riboflavin
Drug
Lead sponsor
Cornea and Laser Eye Institute
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 27, 2026, 3:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Study to Investigate the Feasibility, Reliability and Efficacy of Utilizing OCT to Automate PROSE Fitting

NCT04649177
View directory record Official record
Conditions
Keratoconus, Ocular Surface Disease, Pellucid Marginal Corneal Degeneration, Ectasia, Corneal Trauma, Corneal Scar, Dry Eye Syndromes, Keratoconjunctivitis Sicca, Sjogren's Syndrome
Interventions
Ocular surface optical coherence tomography
Device
Lead sponsor
Boston Sight
Other
Eligibility
21 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Sep 27, 2026, 3:32 PM EDT
Terminated Phase 2 Interventional

CXL-04 A Study of Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas

NCT01956474
View directory record Official record
Conditions
Keratoconus
Interventions
Theralight crosslinking and Riboflavin
Other
Lead sponsor
Cxlusa
Industry
Eligibility
8 Years and older
Enrollment
1,324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Miami, Florida • Atlanta, Georgia • Rockville, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 27, 2026, 3:32 PM EDT
Terminated Phase 2 Interventional

Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross-Linking in Eyes With Keratoconus.

NCT02762253
View directory record Official record
Conditions
Keratoconus
Interventions
Riboflavin drops
Drug
Lead sponsor
Nvision Laser Eye Centers
Industry
Eligibility
12 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
11
States / cities
Camarillo, California • Citrus Heights, California • Fullerton, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Sep 27, 2026, 3:32 PM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Treatment of Keratoconus Using Collagen Cross-Linking

NCT00841386
View directory record Official record
Conditions
Keratoconus
Interventions
Riboflavin-5-phosphate, Sham cross-linking
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
16 Years to 35 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Amherst, New York • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2009 · Synced Sep 27, 2026, 3:32 PM EDT